ClosedGrantWon by MANHATTAN BIOSOLUTIONS, LLCSBIR Phase I SBIR
SBIR Phase I: Genetically Engineered BCG as a Microbe-Based Platform for Vaccination Against COVID-19
National Science Foundation
Closed
NAICS 541715
Source: sbir_sttr
OverviewIntelligenceProposals
Key Details
- Posted Date
- Response Deadline
- NAICS Code
- 541715
- Source
- sbir_sttr
- Award Amount
- $256,000
- Awarded To
- MANHATTAN BIOSOLUTIONS, LLC
Description
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a safe and affordable COVID-19 vaccination technology, with broader utility in managing other contagious diseases. The new platform is
Key Dates
Posted:→Deadline:
Frequently Asked Questions
Is this grant still open?+
No — the response deadline for this grant has passed (August 31, 2021). Browse other active National Science Foundation opportunities on Bureauify.
How do I apply for this grant?+
Review the full solicitation documents on the source website (SAM.gov or Grants.gov), prepare your proposal per the instructions, and submit before the deadline. Use Bureauify to track the opportunity and get reminders.
Who won this grant?+
This grant was awarded to MANHATTAN BIOSOLUTIONS, LLC for $256,000. Use Bureauify to analyze this vendor's contract history and win patterns.
Intelligence
- Win probability analysis
- Competitive landscape
- Incumbent analysis
- Price-to-win estimate
- Similar awards history
Data sourced from sbir_sttr